Walter Ernest Dixon was one of the first to conceive the idea of chemical transmission of nerve effects, that nerves act through the release of a drug-like substance. At the beginning of the century (1906) he suggested that the vagus nerve may act on the heart through the release of an inhibitory muscarine-like substance, and he performed experiments to test his theory. What gave him this idea? He was a pharmacologist and knew that a characteristic feature of an innervated structure like the heart is its sensitivity to chemical substances, that is, to drugs. I think it must have been his intuition, as a pharmacologist, which made him realize that a nerve impulse reaching a chemically sensitive structure like the heart would be a most inefficient stimulus for the purpose for which it was sent out, if it were not endowed with the power to release a drug-like substance. It is worth pointing out in this connexion that all the early contributions to our knowledge of how a nerve impulse is transmitted to an effector organ were made by pharmacologists.
The central synapse is also a chemically sensitive structure. Nerve cells are as sensitive to drugs as are the heart, smooth muscles or gland cells, and to approach the central synapse from the pharmacological point of view may give us information about the functions of the brain which purely electrophysiological methods cannot provide.
To use this approach, however, we need special methods. It is not sufficient to inject drugs intravenously or subcutaneously; we must introduce them into the brain so as to avoid peripheral effects, and we must be able to localize the site of action within the brain. This aim is largely Fig 1 Diagram offrontal section through the cat's brain with implanted Collison cannula for intraventricular injections achieved by allowing the drugs to penetrate the brain from its inner surface, that is, from the cerebral ventricles. Before I come to the main topic of my lecture I shall discuss briefly our methods and, for one drug, how they work.
All our experiments were done on cats, and Fig 1 shows the specially constructed cannula we use to inject drugs into the cerebral ventricles, In an aseptic operation, the cannula is screwed into the skull in such a way that its tip rests in a lateral ventricle. The butt outside the skull is closed by a cap with a rubber diaphragm. Through this diaphragm the drugs are painlessly injected in the following weeks or months without the cat being anesthetized. Fig 2 is an X-ray photograph after an intraventricular injection of iophendylate (Myodil). It indicates the sites reached by drugs injected through such an indwelling cannula, and italso outlines the shape of the ventricular system in the cat. This outline is used for the diagrams of by Feldberg & Sherwood 1963) tricles as well as the third ventricle around the massa intermedia, except for a small part in front of the massa. The aqueduct stands out as a thin line, and the fourth ventricle is seen as a triangle. The Myodil has also entered the subarachnoid space around the brain stem through the foramina of Luschka so the whole ventricular system and parts of the subarachnoid space are flooded. Drugs injected through such a cannula may therefore act on any structure situated near the ventricular lumen and near the surface of the brain stem. How can we distinguish between these sites of action?
This has become possible for those effects which are not abolished by anLesthesia, because we can perfuse the ventricles under anasthesia. With the methods now available we can exclude the subarachnoid space from the perfusion, and we can limit the action of the perfused drug to a given part of the ventricular system.
Methodsfor Perfusing Given Parts ofthe Cerebral Ventricles with Drugs
To exclude the subarachnoid space we perfuse from a lateral ventricle and collect the outflow from a cannula passed through the opened cisterna along the floor of the fourth ventricle into the middle of the aqueduct (Bhattacharya & Feldberg 1958) . With this method, which is illustrated diagrammatically in Fig 3, we exclude from the perfusion not only the subarachnoid space, but also the fourth ventricle.
The passage of a drug can be further limited to a given part of the perfused area by perfusing the other parts with artificial cerebrospinal fluid (CSF); the area perfused remains unchanged. To exclude a drug from one of the two lateral ventricles, both are cannulated and then perfused through the two cannulh, but with separate injectors, one delivering the drug, the other artificial CSF. The outflow is again from the aqueduct. Drugs perfused in this way thus pass only through one lateral ventricle, the third ventricle, and the rostral part of the aqueduct.
This still leaves large areas of grey matter exposed to the perfused drugs. As illustrated in Fig 4, the walls of the anterior horn contain the olfactory grey matter, the septum and caudate nucleus, the walls of the inferior horn, the hippocampus and amygdala. From the third ventricle the drugs may penetrate the hypothalamus and the thalamus, particularly its massa intermedia and habenula, and from the aqueduct they may enter the central grey matter.
The final stage, the regional perfusion with drugs through a given part of this perfused area so that a drug irrigates either only a lateral ventricle, or only its anterior or inferior horn, or the third ventricle, or even only that part of it lying dorsal or ventral to the massa intermedia, is carried out by multiple cannulation of the ventricular system (Carmichael et al. 1964a) . The various modifications are illustrated in Fig 5. Four or five cannulk are used, each inserted into a different part. One cannula acts as an outflow; the others attached to separate injectors serve as inflow. Outflow and inflow through the cannule are marked by correspondingly directed arrows. One, at most two, deliver the drug, the others artificial CSF. The cannulk delivering the drugs are solid black, and the parts of the ventricular system exposed to the drugs are shaded. This method prevents access of the drug to any part perfused with artificial CSF.
A drug is always prevented from entering the right lateral ventricle by perfusing it with artificial CSF delivered through an implanted cannula. This cannula is not shown in the diagrams which outline only the left lateral ventricle, third ventricle and aqueduct, with the cannul; inserted into these cavities.
To perfuse drugs through the left lateral ventricle, three cannule are inserted into this ventricle, one into the anterior horn, one into the inferior horn, and a third, which serves as outflow, into the body. Both the inferior and anterior horn cannulk deliver the drugs. A fourth cannula is inserted into the aqueduct; it serves as inflow, but of artificial CSF, which thus perfuses the third ventricle in retrograde direction, and prevents the drug from entering it.
To perfuse drugs through either the inferior or anterior horn alone the arrangement remains the same, but the drugs are delivered through only one of the two cannule; the other delivers artificial CSF. These three methods of perfusion are illustrated in Fig 5A, B , C.
As shown in Fig 5D, the same arrangement provides a method for perfusing drugs through the third ventricle. For this purpose the drug is delivered through the aqueductal cannula and perfuses the third ventricle in retrograde direction, whilst its entrance into the lateral ventricle is prevented by the perfusion of artificial CSF through the anterior and inferior horn cannulk. With this method it is, however, unavoidable that a small area of the lateral ventricle between the foramen of Monro and the outflow cannula is exposed to the drug. This does not happen when the third ventricle is cannulated and the drug is delivered through this cannula whilst artificial CSF is perfused through the lateral ventricles and the outflow collected from the aqueductal cannula. This method is illustrated in Fig 5E . Fig 5F shows the method for perfusing drugs through either the ventral or dorsal half of the third ventricle. A double-bore cannula is inserted into the third ventricle in such a way that the opening of the inner tube lies ventral, that of the outer tube dorsal to the massa intermedia. The diagram shows the arrangement for the perfusion of drugs through the ventral half. The drug is delivered through the inner, and artificial CSF through the outer tube. For the perfusion of drugs through the dorsal half the procedure is reversed.
At the end of each experiment the perfusion is checked by substituting the dye bromphenol blue for the drug to ascertain which regions are stained, i.e., reached by the drug.
Sites ofAction ofIntraventricular Tubocurarine
With the methods described it is possible to localize the site where a drug acts within the cerebral ventricles when producing its various effects. This will be shown for tubocurarine. Injected intravenously, it produces motor paralysis, a peripheral effect which is used in anasthesia to bring about muscular relaxation. Tubocurarine, however, is also a potent central stimulant, although none of its central effects occurs on intravenous injection. The reason is that it cannot reach the nervous structures when passing through the brain via the blood stream, because for tubocurarine, as for certain other substances, a barrier exists between blood and brain: the blood-brain barrier. With our methods of perfusing the cerebral ventricles we circumvent this barrier.
Why do I choose tubocurarine, a substance which can have no physiological function, since it does not occur naturally in the brain, and which cannot even reach the nervous structures in the brain when injected into the blood stream? There are three reasons: (1) For the purpose of illustrating what the methods can do, tubocurarine is an ideal substance because it has a wide spectrum of central effects which originate not from one but from several sites bordering different parts of the cerebral ventricles. (2) An analysis of the central actions of tubocurarine may lead to a better understanding of some patterns of abnormal brain activity which occur in certain clinical disorders. (3) Tubocurarine is the only substance so far fully analysed with the methods of regional perfusion. So there was really no choice.
In Table 1 the effects produced by tubocurarine when perfused through the cerebral ventricles are summarized under three headings. The autonomic effects, the motor effects and the changes in respiration occurred only when the tubocurarine passed through the third ventricle; for most of these effects the analysis was carried further and the site could be restricted to the walls, of the ventral half of the third ventricle which are formed by the hypothalamus. These actions thus all resulted from an action on the hypothalamus (Carmichael et al. 1964b) .
In contrast, the abnormal activity recorded in the electrocorticogram resulted from an action on structures lining the lateral ventricle and thus occurred only when tubocurarine was perfused through this part of the ventricular system. But the two components of this abnormal discharge, the spikes with intermittent periods of fast activity on the one hand, and the slow waves on the other, were found to have different sites of origin. To produce the spike discharge with episodes of fast activity the tubocurarine had to pass through the inferior horn, to produce the slow waves it had to pass through the anterior hornofa lateral ventricle (Feldberg & Fleischhauer 1962 , 1963 , Carmichael et al. 1964b ).
An illustration of the abnormal electrical activity recorded in the electrocorticogram is given in Fig 6. The upper two records were taken after a few minutes' perfusion of tubocurarine through the inferior horn; they show the onset of the spike discharge with an episode of fast activity followed by a period of electrical silence, that is, a period in which no abnormal activity is recorded. The middle records are obtained from another experiment and show the slow waves on perfusion of tubocurarine through the anterior horn, and the lowest records show what happens when tubocurarine is perfused through both the anterior and inferior horn. Spikes are superimposed on the slow waves and may actually arise from them; the slow waves continue during the episode and during the period of electrical silence which follows it.
Three structures from which the slow waves could originate line the anterior horn: the olfactory grey matter, the caudate nucleus and the septum (Fig 4) . The first has been excluded because the slow waves also appear when the olfactory grey matter has been destroyed electrolytically. No experiments have yet been performed to distinguish between the other two structures, but the septum appears to be the more likely site of origin because it contains structures which may act as a pace-maker for electrical events in the hippocampus (Petsche & Stumpf 1962 ). Fig 4 also shows two structures lining the inferior horn from which the spike discharge with the intermittent periods of fast activity could originate, amygdala and hippocampus. To establish the origin of the spike discharge, needle electrodes were inserted into the amygdala and hippocampus, and records taken simultaneously with the electrocorticogram to find out where the discharge appears first. This would indicate their origin. The result was unequivocal: the spikes appear first in the hippocampus, then in the occipital cortex and last in the amygdala (Fig 7) . We are thus dealing with an action of tubocurarine on the hippocampus, i.e. with a hippocampal discharge.
Although intraventricular tubocurarine acts at at least three separate-sites which lie in the walls of the anterior horn, of the inferior horn and of the third ventricle, the effects originating from these sites interact.
For instance, the abnormal discharge interacts with the myoclonus and with the autonomic responses. This becomes evident when both the lateral and the third ventricle are perfused with tubocurarine. Then both myoclonus and autonomic effects come under the influence of the abnormal discharge and are reinforced by it. Then each slow wave or spike is seen to coincide with a jerk, with a small abrupt widening of the pupils and with a small wave of pilo-erection. The slow waves and spikes trigger off these events.
The interaction of the abnormal discharge on the diencephalic effects of tubocurarine may perhaps help us to obtain a clearer understanding of some features of epilepsy encountered in man. In many forms of human epilepsy, including temporal epilepsy, we can distinguish between two phenomena: an abnormal electrical activity recorded in the electroencephalogram, and the fit, the overt seizure. The abnormal electrical activity may continue for long periods without spread to other regions, that is, without loss of consciousness and without clonic or tonic convulsions. This abnormal electrical activity, or this focal discharge, has features in common with the abnormal discharge produced experimentally in cats when tubocurarine irrigates the lateral ventricle, and it may in fact originate in the hippocampus. In itself, however, it does not produce the fit. Apparently a change in the excitable state of other structures, possibly lying in the diencephalon, is required before the epileptic focal discharge can spread to precipitate the overt seizure, in the same way as the abnormal discharge produced by tubocurarine will trigger off motor effects only when the hypothalamus is stimulated by tubocurarine.
Epilepsy, especially temporal lobe epilepsy, is treated in two ways: by surgical eradication of the deep focal discharging lesion, and by reducing the excitability of the central nervous system by giving a barbiturate. In the experiments on cats with intraventricular tubocurarine, pentobarbitone sodium was found to depress myoclonus without greatly affecting the abnormal discharge.
A D B C E In epilepsy, too, the main action of the barbiturates may therefore not be on the focal discharge itself, but on the excitability of those parts of the brain to which the discharge spreads.
A New Concept ofTemperature Control The latest development in our studies on the action of drugs introduced into the cerebral ventricles has led to a new concept of temperature control in the hypothalamus. Whenever a substance, artificially administered, acts in minute amounts on structures in which it is normallypresent, the problem arises of whether the pharmacological effects observed mimic a physiological function. Through the work of Vogt (1954) and of Amin et al. (1954) , we know that noradrenaline, adrenaline and 5-hydroxytryptamine (5-HT) occur naturally in the walls of the ventral half of the third ventricle, that is, in the hypothalamus: noradrenaline occurs in a concentration of about 1 1lg/g tissue, the others in much weaker concentrations. Fig 8, taken from Vogt's paper, shows the distribution of noradrenaline in the dog's brain. The highest concentration is shown by the black triangles. The same distribution applies for adrenaline and 5-HT. When these amines are injected into the cerebral ventricles they penetrate the hypothalamus and affect body temperature. Hence the question, do these effects mimic a physiological function?
Body temperature is under the control of the hypothalamus. But we do not know what goes on in this structure to bring about this control. Is it the release of noradrenaline, adrenaline and 5-HT as suggested by their pharmacological effects when injected intraventricularly?
How did it happen-that Dr Myers and I investigated the effect of these amines on tem- perature? It happened because the experience gained in two laboratories was brought together, and it illustrates how fruitful that can be. Domer and I (1960) had found that 5-HT injected into the cerebral ventricles of cats produced shivering whereas adrenaline and noradrenaline did the opposite and abolished shivering. A little over a year ago, Dr Myers came to work with me. When I asked him what he had done in the United States he told me that he and Villablanca (1965) had worked with bacterial pyrogens and had found that, injected intraventricularly into cats, they produced not only fever but also vigorous shivering. I then told him of our experiments on shivering and we both realized at once that the following questions had to be answered.
Could it be that pyrogen-induced shivering would also be abolished by intraventricular noradrenaline and adrenaline, and if so, would these catecholamines affect body temperature as well, bring down fever and perhaps even lower normal temperature? And would 5-HT, which on injection into the cerebral ventricles elicits shivering, cause fever when applied in this way, thus being a pyrogen ? Our experiments have answered these questions in the affirmative (Feldberg & Myers 1964a , b, 1965a ventricles through an indwelling cannula lowered rectal temperature for several hours, and not only temperature elevated by bacterial pyrogens but also normal temperature. The effects of adrenaline and noradrenaline on normal temperature are illustrated in Fig 9. Adrenaline is twice as potent as noradrenaline. The injections also stopped shivering which accompanied the fever produced by the bacterial pyrogens. On the other hand, an intraventricular injection of 200 pg of 5-HT, caused a rise in rectal temperature lasting for many hours (Fig 10) .
The hypoand hyper-thermic effects which occur when the amines are injected intraventricularly result from their action on the anterior hypothalamus, for the same changes in temperature occur when the amines are applied by micro-injections to this part of the hypothalamus; only a few micrograms were required, in fact, in one experiment half a microgram produced a fall in temperature of over 0.50 C. However, when the micro-injections were made into the posterior or ventromedial hypothalamus, the amines did not affect body temperature. One additional point may be mentioned. Although the anterior hypothalamus occupies both sides of the wall of the third ventricle, the micro-injections were made unilaterally. Thus excess of free 5-HT or catecholamines in one side of the anterior hypothalamus can and will determine the level of body temperature. The most common changes in temperature are the rise produced by bacterial pyrogens, i.e. the fever of infectious diseases, and the fall which occurs in anesthesia. How can the new concept explain these changes?
The bacterial pyrogens may act by causing a release of 5-HT or augmentation of its release with inhibition of the release of the catecholamines. In addition, they may render the hypothalamus more sensitive to the action of 5-HT, and there is the further possibility that pyrogens do not act solely through the release of the hypothalamic amines, but mimic the effect of 5-HT.
In anesthesia, temperature regulation is abolishedthe animal has become poikilothermictherefore the temperature falls if no external heat is applied. In cats given intravenous injections of 45, 50 and 60 mg/kg of the anmsthetic chloralose the temperature falls (Fig 11) . A similar fall is obtained with intraperitoneal injection of pentobarbitone sodium, but the temperature usually recovers more steeply, and the animal shivers vigorously. The fall in temperature produced by anmsthetics can be attributed to their action on the hypothalamus because they also lower body temperature when given by the intraventricular route in doses too small to be effective on systemic application. In the unanesthetized cat a fall in temperature can be obtained with intraventricular injections of less than 1 mg chloralose or with 3 mg pentobarbitone sodium.
Intraventricular pentobarbitone has a double effect; a fall followed by a rise beyond the preinjection level. With successive injections each fall is followed by a rise, so that finally fever is reached, and the onset of each rise is associated with vigorous shivering. Thus pentobarbitone clearly has a pyrogenic action.
Shivering after intraperitoneal pentobarbitone has been known for a long time, has been used for studying the mechanism of shivering (Lippold et al. 1959) , and is abolished by small amounts of adrenaline or noradrenaline given intraventricularly (Domer & Feldberg 1960) .
With chloralose the analysis was carried a stage further. To restrict its action to the walls of the ventral half of the third ventricle, we proceeded as follows: In cats anmsthesia was induced by pentobarbitone sodium and all parts of the ventricles were perfused with artificial CSF. The anmsthesia naturally produced a fall in temperature, but we waited until anxsthesia lightened and temperature began to rise, and then perfused chloralose through the third ventricle (Fig 12) . When chloralose 1/2,500 was perfused for 15 min through the dorsal half of the third ventricle, the temperature continued to rise. As seen at A, there is no change in the slope of the rise. When the same concentration of chloralose was perfused through the ventral half, also for 15 min (at B), temperature began to fall during the perfusion and continued to do so for over 1 hour, when it had fallen 1'5 degrees Centigrade.
Finally, we could show that micro-infusions of only a few micrograms of chloralose directly into the anterior hypothalamus were sufficient to lower body temperature (Feldberg & Myers 1965b) .
What then is the cause of the fall in temperature during anesthesia? It cannot be explained by the fact that in 'anasthetizing the hypothalamus' the anesthetics render this structure insensitive to the amines, because we found that in both chloralose and pentobarbitone anmsthesia the hypothalamus retains its sensitivity to the amines. Fig 13 shows the postponement of the return to normal temperature by 10 hours due to two intraventricular injections of 50 pg first of adrenaline and then of noradrenaline. Fig 14 shows the effect of intraventricular noradrenaline and 5-HT on the temperature during pentobarbitone sodium anmsthesia. Noradrenaline again postpones the return to normal temperature for several hours, whereas 5-HT has the opposite effect. Injected about 1 hour after the intraperitoneal injection of pentobarbitone sodium and during the phase of falling temperature before the lowest point has been reached, it reverses the fall and a rapid rise to nearly 400 C ensues; this high temperature is then maintained for several hours.
To explain the fall in temperature during anesthesia in the light of the new concept, we have to assume that the anesthetics act by modifying the release of the amines in the hypothalamus. This would also explain plausibly the differences between the changes in temperature in chloralose and in pentobarbitone sodium anesthesia. Whether an anesthetic produces a fall in temperature or a fall followed by a rise associated with shivering, the fundamental mechanism could well be the same: the release of the amines within the hypothalamus. 'With both chloralose and pentobarbitone sodium there may be from the beginning a release or increased release of all three amines, but initially the effect of the catecholamines would mask that of the released 5-HT. This could be due to the fact that the amounts of noradrenaline available for release in the hypothalamus are many times greater than those of 5-HT. The effect of 5-HT would become apparent some time later when the release or increased release of the amines ceased. This appears plausible because on intraventricular injection the hyperthermic effect of 5-HT lasts longer than the hypothermic effect of the catecholamines. The difference in action between the two anesthetics, chloralose and pentobarbitone sodium, might also occur only when their effects on the hypothalamus wear off, and there are various possible ways ofexplaining this difference.
Our purely pharmacological experiments neither prove nor disprove these ideas. To prove them we would have to demonstrate that the amines are actually released in the hypothalamus during anaesthesia. In the last few months we have begun to tackle this problem.
We had to decide whether to look first for the release of the catecholamines or of 5-HT, and we decided on 5-HT. The isolated strip of the rat's stomach fundus is a very sensitive preparation for assaying 5-HT as shown by Vane (1957) . When suspended in a 5 ml bath, it contracts to fess than a nanogram (a millionth of a milligram).
When we added our fluid from the perfused third ventricle to the bath containing such a preparation it contracted, and the contraction was inhibited by small doses of 2-bromo-lysergic acid diethylamide, a specific inhibitor of 5-HT.
This makes it pretty certain that the substance in the perfusate is 5-HT (Feldberg & Myers 1965c.) Although a definite correlation between the amounts of 5-HT released and temperature has not yet been established, there was often a striking coincidence: a rise in 5-HT activity of a sample collected when the low temperature produced by the anesthesia began to rise and the cat started to shiver. One difficulty we encountered was that the samples of perfusate contained interfering substances which made the assay difficult.
One further result may explain a phenomenon which has long puzzled neurosurgeons: the brain fever and the shivering bouts that occur in certain cases of brain injury. We thought we must find out how long it takes for the 5-HT activity to disappear from the perfusate when perfusion of the third ventricle was continued after the cat was killed, i.e. in the dead animal. To our surprise, the 5-HT activity did not decrease, but increased 3 to 24 times in the samples collected during the first 30-60 min after death, and only then diminished gradually. What is the meaning of this post-mortem effect, of this life after death in the hypothalamus?
If we take the view which our pharmacological findings impose upon us, that temperature is the outcome of a fine balance in the release of catecholamines and of 5-HT in the hypothalamus, it would appear that the basal mechanism is the release of 5-HT in order to keep up temperature. As soon as the blood supply to this part of the brain is interfered with, 5-HT is released at an abnormally high rate. This happens after death, and if the animal were not dead its temperature would rise and it would shiver. The same may happen in brain injuries after accidents when small vessels in the hypothalamus may tear and, as a result of an abnormally high release of 5-HT in the regions which no longer receive their normal blood supply, temperature rises and shivering sets in. Supporting evidence for this view may be the finding by.Sachs (1957) of 5-HT in the lumbar cerebrospinal fluid of a number of patients following head injury.
The aim of my lecture was to demonstrate our procedure of approaching the brain from its inner surface, that is, from the cerebral ventricles, because I think this approach may give us new and fundamental information about how the brain works, and this information, we hope, may ultimately also help the clinician.
